Cabergoline
Cabergoline (Dostinex): FDA approval for high prolactin, label warnings on heart valve and tissue fibrosis, echocardiogram monitoring and evidence.
FDA-approved, prescription only · Evidence grade A · Reviewed
- FDA-approvedHigh prolactinHyperprolactinemic disorders in adults
Cabergoline (Dostinex). Dopamine agonist (ergot derivative).
AFDA-approved, prescription only. Evidence grade A: approved, large human trials.
What is Cabergoline?
Cabergoline is an oral dopamine agonist derived from ergot. It lowers prolactin, a hormone made by the pituitary gland.
Is Cabergoline FDA-approved?
FDA approved Dostinex (NDA 020664) on December 23, 1996. It is approved for hyperprolactinemic disorders in adults, either of unknown cause or due to pituitary adenomas. Generics are sold, and it is prescription only. Use in men to manage steroid side effects is not an approved use.
What does the evidence show for Cabergoline?
Human trials in adults with high prolactin support the approved use. Heart valve risk comes from postmarketing reports and studies.
What are the known risks of Cabergoline?
The label has no boxed warning. It warns of heart valve disease and fibrosis of the heart lining, lungs and abdomen, which has often shown up as heart failure. It is contraindicated with existing valve disease or pericardial fibrosis, and the label calls for an echocardiogram before starting and every 6 to 12 months during treatment. WADA does not list cabergoline on its Prohibited List.
How is Cabergoline measured?
A tablet, so there is nothing to draw or calculate.
Sources: FDA: Dostinex prescribing information (2025); FDA: Dostinex approval package (1996); DailyMed: Cabergoline tablets label. This profile does not recommend any dose or use.
For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.
Keep reading
Spot a mistake or an out-of-date fact? Report an error. We check every report against the sources.